Market Characterised By Opportunities And Risks, Aligning With Regional Business Environment

BMI View: The attractiveness of Austria to multinational drugmakers stems from the fact that its population demands high-end patented products and per-capita expenditure on pharmaceuticals and healthcare is high - especially compared with some of its regional peers. However, in light of Western Europe's challenging business environment, BMI believes drug companies will face many challenges in Austria over the next decade, including the country's need to reduce fiscal deficits, the onset of the patent cliff, additional regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new drugs.

To read the full article, please choose one of the following options: